Apalutamide is under clinical development by Johnson & Johnson and currently in Phase II for Prostate Cancer. According to GlobalData, Phase II drugs for Prostate Cancer have a 23% phase transition ...

India's medical device industry, valued at US$12 billion, has become a growing hub for innovation, attracting venture capital ...

Johnson & Johnson announced that on January 5, “out of an abundance of caution,” Johnson & Johnson MedTech temporarily paused the U.S.

We came across a bullish thesis on Johnson & Johnson (NYSE:JNJ) on Business Model Mastery Substack by The Antifragile ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

"Don't Die" tracks Bryan Johnson's unrealistic journey toward peak physical health – unrealistic because not everyone has $2 million to spare.

Kristin Sherman leads startup Kovina Therapeutics, which is still in the early stages of developing ways to stop human ...

Drivers: The market is propelled by a surge in chronic diseases, escalating demand for emergency care services, rising healthcare expenditures globally, and an increase in road accidents and trauma ...

Exclusive: Jane Campbell is one of thousands of women in the UK planning legal action against one of the world’s largest ...

Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...

Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.

But also one that Bryan Johnson ... agree with his methods − medical experts are certainly wary of the scientific basis for his protocols and of him selling products as part of his endeavor ...